Skip to content Skip to footer

MxT = Microfluidics x Therapy

Microfluidic Gene Editing for Cell Therapy Starts Right Here

We transform cancer immunotherapy, cellular engineering and genome editing with our patented non-viral genome editing technology, Hydroporator™

Technology

Hydroporator™: Next-Generation Microfluidic cellular engineering platform accelerating the discovery, development and manufacturing of novel cell therapies

Hydroporator™ is a non-viral microfluidic platform for highly effective delivery of external cargos such as plasmid DNA, mRNA, proteins, CRISPR-Cas9 RNPs, and nanoparticles into primary cells. The Hydroporator™ technology enables high delivery efficiency, easy operation, low cost, high scalability, minimal cell perturbation (i.e., preserved cell function and viability), and cell type/cargo insensitive delivery. Hydroporator™ is free from the challenges from viral transduction, lipofection and electroporation, establishing a new avenue to accelerate cancer immunotherapy, cellular engineering and genome editing.

Fundamental advantages

Icon

Unlimited in cargo type including large sizes

Icon

Maintains viability

Icon

Highly efficient

Icon

Scalable from R&D into clinic

Icon

Effective for variety of cells

Icon

Preserved Cell Viability & Function

Icon

High Speed & Throughput Capability

Icon

Simple and Scalable

Icon

Strong Clinical Applicability

Technologies Efficiency Nanoparticle delivery Primary cell applicability Viability Scalability
(per run)
Cost
Electroporation
(depends on cell and cargo type)

(high Stokes drag)

(low viability)

(depends on cell type)
High
(104-106 cells per run)
$10K to 100K
Microinjection
(theoretically high)

(depends on cell type)
Low
(100 cells per hour)
$10K
(injector only)
Viral transduction
(limited in DNA size)

(packaging failure)

(mutagenesis concern)
Low to High
(depends on viral amount)
High
(preparation)
Lipofection
(depends on cell and cargo type)

(packaging failure)

(low efficiency for suspension cells)

(depends on cell type)
Low to High
(depends on reagent amount)
$1K/50 tests
Hydroporator™
(>90% for human primary T cell)

(> 300 nm)

(immunocyte, stem cell....)

(> 80%)
High
(106 cells per min per channel)
~$1
(chip fabrication)

Table reference: “Microfluidic and nanofluidic intracellular delivery”, Advanced Science (IF=16.806), 2004595 (2021)

Publications

Our Team

Aram Chung, Ph.D.

CEO & Founder

Yeonho Choi, Ph.D.

Executive Director

Soon-Tae Lee, M.D., Ph.D.

Scientific Advisor

Chin-Ha Chung, Ph.D.

Scientific Advisor

Gi-Beom Kim

Director of Engineering

Byeongju Joo

Senior Researcher

Hojong Lee

Assistant Researcher

Jiyoon Jeong

Researcher

Jiyeon Han

Administrative Staff

IR & News

Partners

We are grateful to be collaborating with great partners. With their generous support, we are moving towards achieving our mission. We welcome you to join our steps towards our mission.

Contact

    Contact info

    #1006, Ttukseom-ro 17ga-gil 48, Seongdong-gu, Seoul, 04785, Republic of Korea
    02-2157-4808    contact@mxtbiotech.com

    주식회사 엠엑스티바이오텍

    주소: 서울특별시 성동구 뚝섬로 17가길 48, 성수 에이원센터 1006호
    사업자등록번호: 108-88-02144 대표전화: 02-2157-4808 Contact: contact@mxtbiotech.com

    MxT Biotech © 2021. All Rights Reserved.